259 related articles for article (PubMed ID: 11790297)
1. Endothelin antagonists and heart failure.
Hürlimann D; Enseleit F; Noll G; Lüscher TF; Ruschitzka F
Curr Hypertens Rep; 2002 Feb; 4(1):85-92. PubMed ID: 11790297
[TBL] [Abstract][Full Text] [Related]
2. Endothelin A receptor antagonists in congestive heart failure: blocking the beast while leaving the beauty untouched?
Spieker LE; Noll G; Ruschitzka FT; Lüscher TF
Heart Fail Rev; 2001 Dec; 6(4):301-15. PubMed ID: 11447305
[TBL] [Abstract][Full Text] [Related]
3. Endothelin receptor antagonists in congestive heart failure: a new therapeutic principle for the future?
Spieker LE; Noll G; Ruschitzka FT; Lüscher TF
J Am Coll Cardiol; 2001 May; 37(6):1493-505. PubMed ID: 11345356
[TBL] [Abstract][Full Text] [Related]
4. Endothelin and heart failure.
Nambi P; Clozel M; Feuerstein G
Heart Fail Rev; 2001 Dec; 6(4):335-40. PubMed ID: 11447308
[TBL] [Abstract][Full Text] [Related]
5. Bosentan and the endothelin system in congestive heart failure.
Ellahham SH; Charlon V; Abassi Z; Calis KA; Choucair WK
Clin Cardiol; 2000 Nov; 23(11):803-7. PubMed ID: 11097125
[TBL] [Abstract][Full Text] [Related]
6. Hemodynamic effects of bosentan in patients with chronic heart failure.
Kiowski W; Sütsch G; Oechslin E; Bertel O
Heart Fail Rev; 2001 Dec; 6(4):325-34. PubMed ID: 11447307
[TBL] [Abstract][Full Text] [Related]
7. Role of endothelin in the maintenance of blood pressure in conscious rats with chronic heart failure. Acute effects of the endothelin receptor antagonist Ro 47-0203 (bosentan).
Teerlink JR; Löffler BM; Hess P; Maire JP; Clozel M; Clozel JP
Circulation; 1994 Nov; 90(5):2510-8. PubMed ID: 7955209
[TBL] [Abstract][Full Text] [Related]
8. Selective endothelin-A versus combined endothelin-A/endothelin-B receptor blockade in rat chronic heart failure.
Mulder P; Boujedaini H; Richard V; Derumeaux G; Henry JP; Renet S; Wessale J; Opgenorth T; Thuillez C
Circulation; 2000 Aug; 102(5):491-3. PubMed ID: 10920058
[TBL] [Abstract][Full Text] [Related]
9. Endothelin and endothelin receptor antagonism in heart failure.
Sütsch G; Kiowski W
J Cardiovasc Pharmacol; 2000; 35(4 Suppl 2):S69-73. PubMed ID: 10976786
[TBL] [Abstract][Full Text] [Related]
10. Role of endogenous endothelin in chronic heart failure: effect of long-term treatment with an endothelin antagonist on survival, hemodynamics, and cardiac remodeling.
Mulder P; Richard V; Derumeaux G; Hogie M; Henry JP; Lallemand F; Compagnon P; Macé B; Comoy E; Letac B; Thuillez C
Circulation; 1997 Sep; 96(6):1976-82. PubMed ID: 9323089
[TBL] [Abstract][Full Text] [Related]
11. Chronic oral endothelin type A receptor antagonism in experimental heart failure.
Borgeson DD; Grantham JA; Williamson EE; Luchner A; Redfield MM; Opgenorth TJ; Burnett JC
Hypertension; 1998 Mar; 31(3):766-70. PubMed ID: 9495259
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic and therapeutic potential of the endothelin system in patients with chronic heart failure.
Krum H; Denver R; Tzanidis A; Martin P
Heart Fail Rev; 2001 Dec; 6(4):341-52. PubMed ID: 11447309
[TBL] [Abstract][Full Text] [Related]
13. Endothelin antagonism in experimental ischemic heart failure: hemodynamic, structural and neurohumoral effects.
Mulder P; Richard V; Thuillez C
Heart Fail Rev; 2001 Dec; 6(4):295-300. PubMed ID: 11447304
[TBL] [Abstract][Full Text] [Related]
14. Short-term oral endothelin-receptor antagonist therapy in conventionally treated patients with symptomatic severe chronic heart failure.
Sütsch G; Kiowski W; Yan XW; Hunziker P; Christen S; Strobel W; Kim JH; Rickenbacher P; Bertel O
Circulation; 1998 Nov; 98(21):2262-8. PubMed ID: 9826312
[TBL] [Abstract][Full Text] [Related]
15. Effects of a specific endothelin-converting enzyme inhibitor on cardiac, renal, and neurohumoral functions in congestive heart failure: comparison of effects with those of endothelin A receptor antagonism.
Wada A; Tsutamoto T; Ohnishi M; Sawaki M; Fukai D; Maeda Y; Kinoshita M
Circulation; 1999 Feb; 99(4):570-7. PubMed ID: 9927406
[TBL] [Abstract][Full Text] [Related]
16. Hemodynamic and neurohumoral effects of selective endothelin A (ET(A)) receptor blockade in chronic heart failure: the Heart Failure ET(A) Receptor Blockade Trial (HEAT).
Lüscher TF; Enseleit F; Pacher R; Mitrovic V; Schulze MR; Willenbrock R; Dietz R; Rousson V; Hürlimann D; Philipp S; Notter T; Noll G; Ruschitzka F;
Circulation; 2002 Nov; 106(21):2666-72. PubMed ID: 12438291
[TBL] [Abstract][Full Text] [Related]
17. Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure.
Kiowski W; Sütsch G; Hunziker P; Müller P; Kim J; Oechslin E; Schmitt R; Jones R; Bertel O
Lancet; 1995 Sep; 346(8977):732-6. PubMed ID: 7658874
[TBL] [Abstract][Full Text] [Related]
18. [The pharmacology of endothelin and its antagonist bosentan].
Clozel M; Roux S
Ann Endocrinol (Paris); 2000 Feb; 61(1):75-9. PubMed ID: 10790596
[TBL] [Abstract][Full Text] [Related]
19. Acute and short-term effects of the nonpeptide endothelin-1 receptor antagonist bosentan in humans.
Sütsch G; Bertel O; Kiowski W
Cardiovasc Drugs Ther; 1997 Jan; 10(6):717-25. PubMed ID: 9110115
[TBL] [Abstract][Full Text] [Related]
20. Endothelin receptor antagonists: rationale, clinical development, and role in prostate cancer therapeutics.
Thakkar SG; Choueiri TK; Garcia JA
Curr Oncol Rep; 2006 Mar; 8(2):108-13. PubMed ID: 16507220
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
